What is a stock summary page? Click here for an overview.
Business Description
Ajanta Pharma Ltd
ISIN : INE031B01049
Share Class Description:
NSE:AJANTPHARM: Ordinary SharesCompare
Compare
Traded in other countries / regions
532331.India Index Membership
NIFTY 500 IPO Date
2000-05-29Description
Ajanta Pharma Ltd is a drug manufacturing company with a focus on specialty pharmaceutical products. The company maintains a presence while generating the vast majority of its revenue in India. The company aims to successfully select molecules and products for development while enhancing its research and development capabilities. The company works to develop formulations in different dosages such as tablets, creams, injectables, capsules, liquids, and lotion. The company's manufacturing plants are located in India.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 23.1 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 106.67 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 20.26 | |||||
Beneish M-Score | -2.13 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.9 | |||||
3-Year EBITDA Growth Rate | 8.3 | |||||
3-Year EPS without NRI Growth Rate | 8.1 | |||||
3-Year FCF Growth Rate | 17.5 | |||||
3-Year Book Growth Rate | 7.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 16.52 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.91 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.14 | |||||
9-Day RSI | 53.94 | |||||
14-Day RSI | 53.48 | |||||
3-1 Month Momentum % | -0.8 | |||||
6-1 Month Momentum % | -6.57 | |||||
12-1 Month Momentum % | 29.64 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.07 | |||||
Quick Ratio | 2.14 | |||||
Cash Ratio | 0.83 | |||||
Days Inventory | 271.95 | |||||
Days Sales Outstanding | 92.37 | |||||
Days Payable | 137.67 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.05 | |||||
Dividend Payout Ratio | 0.76 | |||||
3-Year Dividend Growth Rate | 78.5 | |||||
Forward Dividend Yield % | 2.02 | |||||
5-Year Yield-on-Cost % | 3.44 | |||||
3-Year Average Share Buyback Ratio | 1 | |||||
Shareholder Yield % | 1.05 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.46 | |||||
Operating Margin % | 38.51 | |||||
Net Margin % | 20.02 | |||||
FCF Margin % | 14.11 | |||||
ROE % | 25.11 | |||||
ROA % | 19.43 | |||||
ROIC % | 36.33 | |||||
3-Year ROIIC % | 17.87 | |||||
ROC (Joel Greenblatt) % | 40.73 | |||||
ROCE % | 32.35 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 37.46 | |||||
Forward PE Ratio | 31.37 | |||||
PE Ratio without NRI | 37.46 | |||||
Shiller PE Ratio | 48.6 | |||||
Price-to-Owner-Earnings | 47.72 | |||||
PEG Ratio | 2.71 | |||||
PS Ratio | 7.5 | |||||
PB Ratio | 9.09 | |||||
Price-to-Tangible-Book | 9.13 | |||||
Price-to-Free-Cash-Flow | 53.32 | |||||
Price-to-Operating-Cash-Flow | 42.97 | |||||
EV-to-EBIT | 26.95 | |||||
EV-to-EBITDA | 24.19 | |||||
EV-to-Revenue | 7.3 | |||||
EV-to-FCF | 51.71 | |||||
Price-to-GF-Value | 1.25 | |||||
Price-to-Projected-FCF | 4.32 | |||||
Price-to-DCF (Earnings Based) | 2.63 | |||||
Price-to-DCF (FCF Based) | 2.05 | |||||
Price-to-Median-PS-Value | 1.28 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.65 | |||||
Price-to-Graham-Number | 3.95 | |||||
Price-to-Net-Current-Asset-Value | 19.89 | |||||
Earnings Yield (Greenblatt) % | 3.71 | |||||
FCF Yield % | 1.89 | |||||
Forward Rate of Return (Yacktman) % | 10.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ajanta Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₹) | 44,846.5 | ||
EPS (TTM) (₹) | 71.47 | ||
Beta | 0.77 | ||
3-Year Sharpe Ratio | 0.9 | ||
3-Year Sortino Ratio | 2.03 | ||
Volatility % | 31.27 | ||
14-Day RSI | 53.48 | ||
14-Day ATR (₹) | 98.635232 | ||
20-Day SMA (₹) | 2616.01 | ||
12-1 Month Momentum % | 29.64 | ||
52-Week Range (₹) | 2111.05 - 3485 | ||
Shares Outstanding (Mil) | 124.91 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ajanta Pharma Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ajanta Pharma Ltd Stock Events
Event | Date | Price (₹) | ||
---|---|---|---|---|
No Event Data |
Ajanta Pharma Ltd Frequently Asked Questions
What is Ajanta Pharma Ltd(NSE:AJANTPHARM)'s stock price today?
The current price of NSE:AJANTPHARM is ₹2676.00. The 52 week high of NSE:AJANTPHARM is ₹3485.00 and 52 week low is ₹2111.05.
When is next earnings date of Ajanta Pharma Ltd(NSE:AJANTPHARM)?
The next earnings date of Ajanta Pharma Ltd(NSE:AJANTPHARM) is .
Does Ajanta Pharma Ltd(NSE:AJANTPHARM) pay dividends? If so, how much?
The Dividend Yield %  of Ajanta Pharma Ltd(NSE:AJANTPHARM) is 1.05% (As of Today), Highest Dividend Payout Ratio of Ajanta Pharma Ltd(NSE:AJANTPHARM) was 0.76. The lowest was 0.11. And the median was 0.21. The  Forward Dividend Yield % of Ajanta Pharma Ltd(NSE:AJANTPHARM) is 2.02%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |